Tang Capital Management LLC Purchases 4,087,005 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Tang Capital Management LLC boosted its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 225.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 5,900,000 shares of the company’s stock after buying an additional 4,087,005 shares during the period. Tang Capital Management LLC’s holdings in Compass Therapeutics were worth $8,555,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in CMPX. Tower Research Capital LLC TRC boosted its stake in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares during the period. Independent Advisor Alliance bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at $26,000. BNP Paribas Financial Markets bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at $27,000. Mariner LLC bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at $30,000. Finally, ProShare Advisors LLC lifted its position in shares of Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the period. 68.43% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of the company’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Anderman bought 20,000 shares of the stock in a transaction on Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the acquisition, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This represents a 2,000.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 29.80% of the company’s stock.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $2.10 on Friday. Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $4.08. The stock has a market capitalization of $290.39 million, a P/E ratio of -5.68 and a beta of 1.40. The stock has a fifty day moving average of $1.94 and a 200-day moving average of $2.11.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). On average, research analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

CMPX has been the subject of a number of recent analyst reports. Leerink Partnrs upgraded Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. HC Wainwright reiterated a “buy” rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Piper Sandler initiated coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Finally, Jefferies Financial Group boosted their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $13.13.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.